ストックスクリーナーアプリを入手
73.02
3.82%
-2.90
アフターアワーズ：
73.02
Nektar Therapeutics (NKTR) 最新ニュース
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse
Nektar Therapeutics (NKTR) Stock Slides As Cash Burn Clouds Pipeline Progress - simplywall.st
NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits
NKTR SWOT Analysis: Financial Challenges and Growth Potential Revealed in 10-Q Filing - GuruFocus
NKTR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Nektar Therapeutics (NKTR) Could Be 52% Undervalued After Q2 Earnings Surprise - Yahoo Finance
Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds - Stock Titan
Biotechnology Value Fund group (NKTR) discloses 7.1% beneficial stake in Nektar - Stock Titan
Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up? - Sahm
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch - Yahoo Finance
Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus - Yahoo Finance
Piper Sandler Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $192 - moomoo.com
Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.st
Boost Run, Nektar Therapeutics, Swarmer - TradingView
Nektar Therapeutics Q2 2026 Earnings Call Summary - Yahoo Finance
Nektar Therapeutics Boosts Cash to Over $1 Billion After Major Dilutive Equity Raises - Minichart
NEKTAR THERAPEUTICS Q2 2026: Revenue $10.1M, EPS $(1.23) — 10-Q Summary - TradingView
Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss - Stock Titan
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics Cash Reaches $1.02 Billion After $373.8 Million Offering - Minichart
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028 - The Clinical Trial Vanguard
Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: R - GuruFocus
Nektar Therapeutics Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours - Investing.com Nigeria
Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call - Benzinga
Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS - MarketBeat
Nektar Therapeutics reports results for the quarter ended June 30Earnings Summary - TradingView
Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Is Nektar Therapeutics (NKTR) Oversold After Q2 Earnings Miss? G - GuruFocus
Nektar Therapeutics posts Q2 2026 net loss $40.6M; cash and investments $1.023B - TradingView
Nektar Therapeutics Q2 Loss Narrows, Revenue Declines - marketscreener.com
Nektar: Q2 Earnings Snapshot - kare11.com
Nektar Reports $40.6 Million Second-Quarter Loss as Revenue Reaches $10.1 Million - Quiver Quantitative
Earnings Flash (NKTR) Nektar Therapeutics Posts Q2 Loss $1.23 Per Share, vs. FactSet Est of $1.97 Loss - marketscreener.com
Nektar Therapeutics Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c - StreetInsider
Nektar Q2 2026 Earnings: Phase 3 Spending Rises as Cash and Investments Top $1 Billion - TradingKey
Earnings Flash (NKTR) Nektar Therapeutics Reports Q2 Revenue $10.1M, vs. FactSet Est of $10.4M - marketscreener.com
BRIEF-Nektar Therapeutics Q2 EPS USD -1.23 - TradingView
Nektar Therapeutics Announces Second Quarter 2026 Financial Results - PR Newswire
Nektar Therapeutics reports Q2 2026 loss of $40... - Pluang
Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
California State Teachers Retirement System Grows Stock Position in Nektar Therapeutics $NKTR - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect - ACCESS Newswire
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm - Morningstar
Lawsuit alleges Nektar Therapeutics misled inve... - Pluang
Nektar Therapeutics $NKTR Shares Sold by Renaissance Technologies LLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
CCORF Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $153 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics - The National Law Review
Is Global Phase 3 ZENITH AD Rezpegaldesleukin Program Altering The Investment Case For Nektar Therapeutics (NKTR)? - simplywall.st
Healthcare of Ontario Pension Plan Trust Fund Takes $1.14 Million Position in Nektar Therapeutics $NKTR - MarketBeat
Enterprise value to EBITDA forward of Nektar Therapeutics – NASDAQ:NKTR - TradingView
Nektar Therapeutics (NKTR) Expected to Post Quarterly Earnings on Thursday - MarketBeat
Nektar Therapeutics $NKTR Shares Purchased by ADAR1 Capital Management LLC - MarketBeat
Nektar CEO Will Review Second-Quarter Results in Aug. 13 Webcast - Stock Titan
Nektar Therapeutics (NKTR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nektar Therapeutics (NKTR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Is Nektar Therapeutics (NKTR) Undervalued On Its Phase 3 Rezpegaldesleukin Launch? - simplywall.st
Nektar: Sanofi’s Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis (NKTR) - Seeking Alpha
Nektar Therapeutics (NKTR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Stockholders to Connect - ACCESS Newswire
Nektar Therapeutics (NKTR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nektar Therapeutics (NKTR) Institutional Confidence - TradingKey
NKTR|Nektar Therapeutics|Price:70.004|Chg%:-0.721 - TradingKey
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):